

iECURE, a mutation-agnostic in vivo gene editing company, has secured $50 million in Series A financing. Versant Ventures and OrbiMed Advisors led the round.
Source: Press Release
iECURE, a mutation-agnostic in vivo gene editing company, has secured $50 million in Series A financing.
iECURE, a mutation-agnostic in vivo gene editing company, has secured $50 million in Series A financing. Versant Ventures and OrbiMed Advisors led the round.
Source: Press Release
Copyright PEI Media
Not for publication, email or dissemination